These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2230 related articles for article (PubMed ID: 21130701)

  • 1. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
    Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
    Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
    Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
    Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
    Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
    Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct and opposite effects of leukemogenic
    Fortin J; Chiang MF; Meydan C; Foox J; Ramachandran P; Leca J; Lemonnier F; Li WY; Gams MS; Sakamoto T; Chu M; Tobin C; Laugesen E; Robinson TM; You-Ten A; Butler DJ; Berger T; Minden MD; Levine RL; Guidos CJ; Melnick AM; Mason CE; Mak TW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2208176120. PubMed ID: 36652477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
    Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
    Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
    Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
    Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
    Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
    Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
    Inoue S; Li WY; Tseng A; Beerman I; Elia AJ; Bendall SC; Lemonnier F; Kron KJ; Cescon DW; Hao Z; Lind EF; Takayama N; Planello AC; Shen SY; Shih AH; Larsen DM; Li Q; Snow BE; Wakeham A; Haight J; Gorrini C; Bassi C; Thu KL; Murakami K; Elford AR; Ueda T; Straley K; Yen KE; Melino G; Cimmino L; Aifantis I; Levine RL; De Carvalho DD; Lupien M; Rossi DJ; Nolan GP; Cairns RA; Mak TW
    Cancer Cell; 2016 Aug; 30(2):337-348. PubMed ID: 27424808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
    Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
    Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of novel mutations in epigenetic modifiers in AML.
    Abdel-Wahab O; Patel J; Levine RL
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutations in acute myeloid leukemia.
    Rakheja D; Konoplev S; Medeiros LJ; Chen W
    Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
    Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
    [No Abstract]   [Full Text] [Related]  

  • 17. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
    Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
    PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations.
    Kim YH; Pierscianek D; Mittelbronn M; Vital A; Mariani L; Hasselblatt M; Ohgaki H
    J Clin Pathol; 2011 Oct; 64(10):850-2. PubMed ID: 21690245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of IDH1/2 and TET2 mutations in myeloid disorders.
    Inoue S; Lemonnier F; Mak TW
    Int J Hematol; 2016 Jun; 103(6):627-33. PubMed ID: 26980223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 112.